Sanofi India approves Q3 FY25 results, declares ₹75 interim dividend with Nov 7 record date
Sanofi India approved Q3 FY25 results, reporting ₹4,754 crore revenue and ₹760 crore profit from continuing operations. It declared an interim dividend of ₹75 per share with November 7, 2025, as the record date.
The declaration of an interim dividend directly impacts shareholders positively. The release of quarterly and nine-month financial results provides important insights into the company's performance, influencing investor perception and stock valuation. The new distribution agreement for the OAD business could also have a medium-term impact on business operations.
The declaration of a significant interim dividend of ₹75 per share is positive for shareholders. However, the Q3 FY25 revenue and profit from continuing operations showed a year-on-year decline compared to Q3 FY24 (Revenue from Operations: ₹4,754 crore vs ₹5,240 crore; Profit for the period: ₹760 crore vs ₹822 crore), offsetting some of the positive sentiment from the dividend and 9-month profit growth.
Sanofi India Limited's Board of Directors, at its meeting on Wednesday, October 29, 2025, approved the unaudited financial statements for the quarter and nine months ended September 30, 2025. Key financial highlights from continuing operations are: * For the quarter ended September 30, 2025: * Revenue from Operations: ₹4,754 crore * Profit before tax: ₹1,023 crore * Profit for the period: ₹760 crore * For the nine months ended September 30, 2025: * Revenue from Operations: ₹14,176 crore * Profit before tax: ₹3,617 crore * Profit for the period: ₹2,650 crore The Board also declared an interim dividend of ₹75 per equity share of face value ₹10 each for the year 2025. This dividend will be paid within 30 days from the declaration date. Friday, November 7, 2025, has been fixed as the Record Date for this interim dividend. The company also noted an exceptional item of (₹273) crore for the quarter. Effective July 16, 2025, Sanofi India entered a promotion and distribution agreement with Emcure Pharmaceuticals Limited for its Oral Anti-diabetic (OAD) business products.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.